Notably, as early diagnosis remains critical, our findings, together with patient preference for non-invasive disease monitoring methods, provide a rationale to explore whether polyamines in patient saliva could be used as a viable biomarker for disease detection, patient stratification, and prediction of prophylactic and therapeutic responses to CaSR NAM treatment for IPF. The gene discussed is CASR; the disease is idiopathic pulmonary fibrosis.